Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome

被引:67
作者
Bannink, EMN
Raat, H
Mulder, PGH
Keizer-Schrama, SMPFD
机构
[1] Childrens Hosp, Dept Pediat, Div Endocrinol, Erasmus MC Sophia, NL-3000 CB Rotterdam, Netherlands
[2] Univ Rotterdam, Dept Publ Hlth, Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Univ Rotterdam, Dept Epidemiol & Biostat, Med Ctr, Erasmus MC, Rotterdam, Netherlands
关键词
D O I
10.1016/j.jpeds.2005.08.043
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To evaluate health-related quality of life (HRQoL) in young women with Turner syndrome ITS) after long-term growth hormone (GH) therapy and induced puberty and to analyze whether HRQoL was influenced by auxologic parameters, pubertal development, or subjective parameters. Study design The study group comprised 49 women with TS, mean (standard deviation) age 19.6 ( +/- 3.0) years, all former participants of 2 GH studies, 6 months after GH discontinuation. Puberty was induced by estrogen treatment, at mean age 12.9 ( +/- 1.1) years. HRQoL was measured by self-reports of the 2 generic questionnaires, SF36 and TAAQOL. As an additional source of information on HRQoL, we applied parental proxy reports. Results HRQoL of the women with TS was normal. Remarkably, the women with TS had higher HRQoL scores on some of the scales, including "social functioning" and "role-emotional." Satisfaction with height and breast development had a positive influence on several HRQoL scales. Conclusions The young women with TS who reached normal height and had age-appropriate pubertal development reported normal HRQoL. The relatively high scores on some of the HRQoL scales can be explained by an estrogen effect or by a possible response shift, indicating a different internal reference in women with TS. We hypothesize that GH and estrogen treatment positively influenced HRQoL in young women with TS.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 36 条
  • [1] Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations
    Aaronson, NK
    Muller, M
    Cohen, PDA
    Essink-Bot, ML
    Fekkes, M
    Sanderman, R
    Sprangers, MAG
    Velde, AT
    Verrips, E
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) : 1055 - 1068
  • [2] [Anonymous], [No title captured]
  • [3] BANNICK E, 2004, HORM RES S2, V62, P127
  • [4] Quality of life in short adults
    Busschbach, JJV
    Rikken, B
    Grobbee, DE
    De Charro, FT
    Wit, JM
    [J]. HORMONE RESEARCH, 1998, 49 (01) : 32 - 38
  • [5] Quality of life determinants in young women with Turner's syndrome after growth hormone treatment:: Results of the StaTur population-based cohort study
    Carel, JC
    Ecosse, E
    Bastie-Sigeac, I
    Cabrol, S
    Tauber, M
    Léger, J
    Nicolino, M
    Brauner, R
    Chaussain, JL
    Coste, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) : 1992 - 1997
  • [6] *CENTR BUR STAT, 1993, STAND OCC CLASS 1992
  • [7] De Judicibus MA, 2004, ADOLESCENCE, V39, P551
  • [8] Gravholt CH, 1999, CLIN ENDOCRINOL, V50, P791
  • [9] TURNER SYNDROME - FINAL HEIGHT, GLUCOSE-TOLERANCE, BONE-DENSITY AND PSYCHOSOCIAL STATUS IN 25 ADULT PATIENTS
    HOLL, RW
    KUNZE, D
    ETZRODT, H
    TELLER, W
    HEINZE, E
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1994, 153 (01) : 11 - 16
  • [10] Health related quality of life and health status in adult survivors with previously operated complex congenital heart disease
    Kamphuis, M
    Ottenkamp, J
    Vliegen, HW
    Vogels, T
    Zwinderman, KH
    Kamphuis, RP
    Verloove-Vanhorick, SP
    [J]. HEART, 2002, 87 (04) : 356 - 362